PD-1-based checkpoint inhibition has failed as monotherapy in many solid cancer entities, including pancreatic carcinoma, due to low PD-L1 expression, low tumor neoantigen expression, adverse epigenetic changes, and an immunosuppressive tumor microenvironment. The gene discussed is CD274; the disease is exocrine pancreatic carcinoma.